Blarcamesine Shows Promising Results in Alzheimer’s Phase 2b/3 Trial

 Anavex Life Sciences has announced groundbreaking results from its recent Phase 2b/3 clinical trial
involving the investigational drug blarcamesine. This trial assessed the drug’s
efficacy among patients suffering from early Alzheimer’s disease (AD). The
company’s findings indicate a significant reduction in pathological amyloid-ß
biomarkers and a notable slowdown in brain atrophy, as observed through MRI scans. 

The trial, conducted across 52 research centers in five countries, enrolled 508
participants with early symptomatic AD. Participants were randomly assigned to
receive either blarcamesine or a placebo for a duration of 48 weeks. The
primary endpoints of the study included cognitive and functional efficacy,
measured by the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and
the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) subscales. 

Significantly, blarcamesine-treated patients exhibited increases in validated biomarkers of
amyloid-ß pathology, particularly in the plasma Aβ42/40 ratio. These results
suggest a strong antiamyloid effect of the drug. Additionally, MRI scans showed
a significant reduction in brain volume loss compared to the placebo group,
further substantiating the potential of blarcamesine in slowing cognitive decline.

Anavex highlighted the drug’s safety profile, noting that the most common
adverse event reported was dizziness, which was mostly mild to moderate in
severity and transient in nature. The safety and tolerability of blarcamesine
make it a promising candidate for oral administration. 

Marwan Noel Sabbagh, MD, and Michael Weiner, MD, both notable figures in neurology, have
expressed optimism about the potential of Anavex’s drug to make a substantial
impact on AD treatment. According to Christopher U Missling, PhD, CEO of Anavex Life Sciences, the
positive outcomes from this study underscore the company’s commitment to
advancing innovative treatments for Alzheimer’s disease. 

In summary, the trial’s results position blarcamesine as a potential new treatment option that
could offer both efficacy and convenience for patients with early Alzheimer’s
disease, marking a significant milestone for Anavex Life Sciences. Refer to this article for related information. 

Follow their Twitter page on https://twitter.com/AnavexLifeSci